Logo

CELU

Celularity Inc.

CELU

Celularity Inc. • NASDAQ
$1.99 ▲ 0.25% (+0.01)
Market Cap $47.75 M
52w High $4.35
52w Low $1.00
Dividend Yield 0%
P/E -0.6
Volume 13.20K
Outstanding Shares 24.05M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $5.284M ▼ $16.166M ▼ $-23.073M ▲ -436.658% ▼ $-0.876 ▲ $-19.733M ▲
Q2-2025 $5.736M ▼ $16.358M ▼ $-24.524M ▼ -427.545% ▼ $-1.021 ▼ $-20.747M ▼
Q1-2025 $11.426M ▼ $18.358M ▼ $-19.754M ▼ -172.886% ▼ $-0.84 ▼ $-15.483M ▼
Q4-2024 $18.132M ▲ $20.069M ▲ $-13.293M ▲ -73.312% ▲ $-0.595 ▲ $-7.597M ▲
Q3-2024 $9.296M $16.94M $-16.098M -173.171% $-0.733 $-12.452M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $120K ▼ $114.239M ▼ $134.333M ▼ $-20.094M ▲
Q2-2025 $863K ▲ $120.283M ▼ $145.78M ▲ $-25.497M ▼
Q1-2025 $293K ▼ $128.876M ▼ $134.382M ▲ $-5.506M ▼
Q4-2024 $738K ▲ $132.682M ▲ $123.845M ▲ $8.837M ▼
Q3-2024 $133K $128.84M $111.56M $17.28M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-23.076M ▲ $-4.159M ▼ $0 $3.478M ▲ $-743K ▼ $-4.159M ▼
Q2-2025 $-24.524M ▼ $-998.999K ▲ $0 $1.631M ▼ $570K ▲ $-999K ▲
Q1-2025 $-19.754M ▼ $-2.993M ▼ $0 ▲ $2.32M ▲ $-673K ▼ $-2.993M ▼
Q4-2024 $-13.293M ▲ $1.594M ▲ $-1.556M ▼ $643K ▲ $681K ▲ $1.538M ▲
Q3-2024 $-16.098M $-144K $-35K $-79K $-258K $-179K

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
License Royalty and Other
License Royalty and Other
 $0 ▲$0 ▲$0 ▲$0 ▲
Product
Product
 $10.00M ▲$10.00M ▲$0 ▼$0 ▲
Service
Service
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Celularity’s income statement shows a company still in the early, high‑investment phase. Revenue is very small but has been edging higher, helped by its biomaterials business. At the same time, operating losses remain sizeable, meaning day‑to‑day activities cost much more than the company brings in. While the most recent year shows some improvement in losses compared with the prior year, the business is still far from covering its expenses with its own sales. Earnings per share have been mostly negative and volatile, reflecting both ongoing losses and capital structure changes, including a reverse stock split.

Balance Sheet

Balance Sheet The balance sheet reflects a lean and financially stressed profile. Total assets have steadily shrunk over the last few years, and the cash cushion is now very thin. Debt has stayed in place, so leverage is meaningful relative to the company’s small asset base. Equity improved from a deeply negative position a few years ago to a modest positive level after the SPAC period, but it has since been eroded by continued losses. Overall, the company appears to have limited financial flexibility and is sensitive to any funding disruptions.

Cash Flow

Cash Flow Celularity consistently consumes cash rather than generating it. Operating cash flow has been negative every year, showing that the core business and R&D efforts are not self‑funding. Free cash flow has also remained negative, although heavy capital spending is not the main issue; the main driver is that operating expenses and development costs substantially exceed incoming cash from customers. This pattern suggests an ongoing dependence on external capital raises or partnerships to keep advancing its programs and covering day‑to‑day needs.

Competitive Edge

Competitive Edge Competitively, Celularity occupies a differentiated niche within cell therapy by focusing on placenta‑derived, “off‑the‑shelf” products. Its vertical integration, proprietary platform, and sizable manufacturing facility give it technical and operational advantages that are not trivial to copy. A portfolio of biomaterial products already on the market provides some commercial proof of execution and a foothold with clinicians. However, it competes in a crowded and well‑funded biotech landscape, where larger players have deeper resources and more diversified pipelines. Its small scale, limited cash, and early clinical stage position make it vulnerable if trial results, partnerships, or funding do not break in its favor.

Innovation and R&D

Innovation and R&D Innovation is the core of Celularity’s story. The company is pushing a broad pipeline built on placental‑derived natural killer cells, CAR T‑cells, and stromal cells, all designed to be readily available therapies rather than custom‑made for each patient. Its IMPACT platform, in‑house manufacturing, and biobanking capabilities support this ambition at scale. Multiple product candidates target oncology and regenerative indications, while approved biomaterial products show the same underlying science already at work in the clinic. Celularity is also pursuing collaborations and data‑driven R&D to stretch its limited resources. The flip side is that this model is extremely research‑intensive, with long timelines and high scientific, regulatory, and execution risk before any large commercial payoff can be realized.

Summary

Overall, Celularity is a highly innovative but financially fragile clinical‑stage biotech. The company has a distinctive scientific angle, strong technical infrastructure, and a mix of pipeline programs and commercial biomaterials that together form an interesting platform story. At the same time, revenues are still tiny, losses are persistent, cash is thin, and the business depends heavily on outside funding and successful partnerships. The future trajectory will be driven far more by clinical data, regulatory milestones, and deal‑making than by the current financials, which mainly underscore the urgency of proving its science and scaling its commercial model before financial constraints become more pressing.

NEWS

October 30, 2025 · 8:00 AM UTC

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

Read more

October 14, 2025 · 8:45 AM UTC

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

Read more

September 3, 2025 · 8:00 AM UTC

Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

Read more